Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

NCT04849364 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

52

Enrollment

OTHER

Sponsor class

Stopped Funder Decision

Conditions

Breast Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Capecitabine
DRUG: Talazoparib
DRUG: Pembrolizumab
DRUG: Inavolisib

Sponsor

Bryan Schneider, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]